Sage Eva K, Schmid Thomas E, Sedelmayr Michael, Gehrmann Mathias, Geinitz Hans, Duma Marciana N, Combs Stephanie E, Multhoff Gabriele
Department of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München (TUM), Germany.
Department of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München (TUM), Germany; HelmholtzZentrum München, Department of Radiation Sciences (DRS), Institute of Innovative Radiotherapy (iRT), Germany; Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partner Site Munich, Germany.
Radiother Oncol. 2016 Jan;118(1):176-80. doi: 10.1016/j.radonc.2015.11.016. Epub 2015 Dec 9.
Breast cancer is the most common cancer in women worldwide and surgery, radiotherapy (RT) and chemotherapy (ChT) are frequently used to treat this cancer. Adjuvant RT has been shown to cause long-term changes in lymphocyte counts in the peripheral blood. Herein, the time course of changes in lymphocyte subpopulations upon RT was studied in patients with and without adjuvant ChT in order to explore its potential clinical impact.
Total lymphocyte counts and the composition of lymphocyte subpopulations before RT (t0), after 30 Gy (t1), at the end of RT (t2), and 6 weeks (t3), 6 months (t4), and 1 year (t5) after RT were studied by flow cytometry.
Absolute lymphocyte counts were significantly lower in all breast cancer patients (n=40) before and also 1 year after RT compared to healthy controls. The percentage of CD3(+)/CD4(+) helper T cells and FoxP3(+) regulatory T cells increased significantly in patients without adjuvant ChT. Different NK cell subpopulations dropped during RT in patients with and without ChT, but recovered to initial levels 6months after RT (t4). During RT (t0-t2) the percentage of CD19(+) B cells significantly dropped in patients without ChT, but gradually increased in patients with adjuvant ChT. Both patient groups reached initial levels 6 months after RT (t4).
Different lymphocyte subpopulations respond differently to RT with and without adjuvant ChT. CD4(+) T cells increase during RT, whereas NK cells and B cells decrease in patients without ChT, but recover within 6 months after RT. Treg cells gradually increase in patients without ChT from t0 to t5, but not in patients with adjuvant ChT.
乳腺癌是全球女性中最常见的癌症,手术、放疗(RT)和化疗(ChT)常用于治疗该癌症。辅助放疗已被证明会导致外周血淋巴细胞计数的长期变化。在此,为了探索其潜在的临床影响,我们研究了接受和未接受辅助化疗的患者放疗后淋巴细胞亚群变化的时间进程。
通过流式细胞术研究放疗前(t0)、30 Gy放疗后(t1)、放疗结束时(t2)以及放疗后6周(t3)、6个月(t4)和1年(t5)时的总淋巴细胞计数和淋巴细胞亚群组成。
与健康对照组相比,所有乳腺癌患者(n = 40)在放疗前和放疗后1年的绝对淋巴细胞计数均显著降低。在未接受辅助化疗的患者中,CD3(+)/CD4(+)辅助性T细胞和FoxP3(+)调节性T细胞的百分比显著增加。无论是否接受化疗,放疗期间NK细胞亚群均下降,但在放疗后6个月(t4)恢复到初始水平。在放疗期间(t0 - t2),未接受化疗的患者中CD19(+) B细胞的百分比显著下降,但在接受辅助化疗的患者中逐渐增加。两组患者在放疗后6个月(t4)均达到初始水平。
不同的淋巴细胞亚群对有或无辅助化疗的放疗反应不同。放疗期间CD4(+) T细胞增加,而未接受化疗的患者中NK细胞和B细胞减少,但在放疗后6个月内恢复。未接受化疗的患者中Treg细胞从t0到t5逐渐增加,但接受辅助化疗的患者中则不然。